GAD-alum treatment induces GAD65-specific CD4+ CD25highFOXP3+ cells in type 1 diabetic patients
M Hjorth, S Axelsson, A Rydén, M Faresjö… - Clinical …, 2011 - Elsevier
Type 1 diabetes results from autoimmune destruction of insulin producing pancreatic β-cells.
We have shown that treatment with alum-formulated glutamic acid decarboxylase 65 (GAD-
alum) preserved residual insulin secretion and induced antigen-specific responses in
children with recent onset type 1 diabetes. The aim of this study was to further investigate the
immunomodulatory effect of GAD-alum, focusing on CD4+ CD25high cells and their
association to cytokine secretion. Samples obtained 21 and 30months after the initial …
We have shown that treatment with alum-formulated glutamic acid decarboxylase 65 (GAD-
alum) preserved residual insulin secretion and induced antigen-specific responses in
children with recent onset type 1 diabetes. The aim of this study was to further investigate the
immunomodulatory effect of GAD-alum, focusing on CD4+ CD25high cells and their
association to cytokine secretion. Samples obtained 21 and 30months after the initial …